α glucosidase

α-Glucosidase (α-D-Glucosidase) is a carbohydrate hydrolyzing enzyme that catalyzes the release of α-glucose from the non-reducing end of the substrate, playing a vital role in glucose absorption by the small intestine. Inhibiting α-Glucosidase effectively manages non-insulin-dependent diabetes mellitus (NIDDM).

α-Glucosidase-IN-26 (Compound 7i), with an IC50 value of 4.63 µM, functions as an α-glucosidase inhibitor and is utilized in type 2 diabetes mellitus (T2DM) research [1].

α-Glucosidase-IN-28 (Compound 18) is an α-glucosidase inhibitor with an IC50 of 0.62 μM and Ki of 3.93 μM, interacting with the enzyme's original binding site (OBS) and forming multiple hydrophobic interactions with adjacent amino acids. This compound is used in diabetes and related diseases research [1].

α-Glucosidase-IN-29 (compound 19) is an inhibitor of α-glucosidases with an IC50 of 1.21 μM and a Ki of 1.80 μM, used in diabetes and related disease research [1].

α-Glucosidase-IN-31 (compound R1) is a potent oral α-Glucosidase inhibitor with an IC50 of 10.1 μM, demonstrating significant blood glucose reduction and antidiabetic activity [1].

α-Glucosidase-IN-33 (compound 7c), with an IC50 of 2.39 μM, is a potent α-glucosidase inhibitor, pertinent to type 2 diabetes and hyperglycemia research [1].

α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor with an IC50 of 2.90 μM, applicable in type 2 diabetes and hyperglycemia research [1].

α-Amylase α-Glucosidase-IN-5 (compound 4l) functions as a dual inhibitor, effectively inhibiting both α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50 values of 5.96 μM and 1.62 μM, respectively, exhibiting potential for antidiabetic activity [1].

α-Glucosidase-IN-36 (compound 5g) is a potent inhibitor of α-glucosidase, with an IC50 value of 6.69 ± 0.18 μM and inhibition constants (Ki and Kis) of 1.65 μM and 4.54 μM, respectively. It likely suppresses α-glucosidase by interacting with its active site and altering the enzyme's secondary structure. The compound is relevant for research on type 2 diabetes mellitus (T2DM) [1].

α-Amylase α-Glucosidase-IN-3 (Compound 17) is a dual inhibitor of α-Amylase and α-Glucosidase, with IC50 values of 0.70 μM and 1.10 μM, respectively, applicable for type-II diabetes mellitus research [1].

α-Glucosidase-IN-27 (compound 8l), an α-glucosidase inhibitor with an IC50 of 25.78 μM, demonstrates potential for type 2 diabetes (D2M) research [1].

α-Glucosidase-IN-25 (Compound (R)-8k) acts as a competitive inhibitor for α-glucosidase with an inhibitory concentration 50 (IC50) of 1.19 μM, making it applicable in anti-diabetic research [1].

α-Glucosidase-IN-30 (compound 8c) is a potent, orally active competitive inhibitor of α-glucosidase, with a K i of 40.0 µM and an IC50 of 49.0 µM. Non-cytotoxic to both cancerous MCF-7 and normal HDF cell lines, it is suitable for Type 2 diabetes research [1].

α-Amylase α-Glucosidase-IN-4 (compound 5), a dual inhibitor targeting α-amylase (Amylases) and α-glucosidase (Glucosidase), exhibits potent inhibition with IC50 values of 1.10 μM and 0.15 μM respectively, and is noted for its potential antidiabetic activity [1].

α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive inhibitor of α-glucosidase that is orally active with an IC50 of 3.07 μM. It forms a complex with α-glucosidase via hydrogen bonding and hydrophobic interactions, inducing conformational and secondary structure changes that inhibit the enzyme's activity. This compound is utilized in diabetic disease research [1].

α-Glucosidase-IN-42 (Compound 26), a 9-O-berberrubine carboxylate derivative, exhibits potent α-glucosidase inhibitory activity with an IC50 of 1.61 μM and has potential for use in antidiabetic research [1].

α-Glucosidase-IN-41 (compound 5o), a potent inhibitor of α-glucosidase, induces alterations in the enzyme's secondary structure, thereby impeding its catalytic function. This compound is utilized in the study of diabetes mellitus [1].

α-Glucosidase-IN-40 (compound 5) is a noncompetitive inhibitor of the α-glucosidase enzyme, with an inhibitory concentration (IC50) of 24.62 μM [1].

α-Glucosidase-IN-39 is a potent α-glucosidase enzyme inhibitor with an IC50 value of 869.06 ppm, applicable for antidiabetic studies [1].

α-Glucosidase-IN-38 (Compound 11j) is a potent α-glucosidase inhibitor with an IC50 of 12.44±0.38 μM, playing a significant role in Diabetes mellitus (DM) management [1].

α-Glucosidase-IN-23 is an orally active inhibitor of α-glucosidase that can decrease blood glucose levels by inhibiting α-glucosidase (IC50 = 4.48 μM).

α-Glucosidase-IN-22 is a selective inhibitor of α-glucosidase (IC50=0.64 μM). α-Glucosidase-IN-22 has antidiabetic activity and has potential in type 2 diabetes (T2DM) studies.

α-Glucosidase-IN-72 (compound 5i), a 2,4-dichloro-N-phenylacetamide derivative, functions as an α-glucosidase inhibitor with an inhibitory concentration (IC 50) of 6 μM. Notably, it does not adhere to Lipinski's rule of five and is not a cancer inducer.

α-Glucosidase-IN-73 (compound 16b), an α-Glucosidase inhibitor, exhibits an IC 50 value of 0.158 μM and possesses the ability to activate PPAR γ. This compound is applicable in studies focusing on anti-diabetic and anti-inflammatory treatments.